亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Healthcare Utilization in Patients With Chronic Rhinosinusitis With Nasal Polyps – Analysis of the Reg-ent Clinical Data Registry

医学 杜皮鲁玛 鼻息肉 危险系数 队列 内科学 回顾性队列研究 比例危险模型 慢性鼻-鼻窦炎 鼻窦炎 队列研究 药店 过敏 逻辑回归 鼻内镜手术 外科 共病 皮肤病科 年轻人 抗生素 入射(几何) 流行病学 嗜酸性粒细胞增多症 医疗保健 病史 相对风险
作者
Christina H. Fang,Denisa Elena Ferastraoaru,Hyun Song,Richard V. Smith,Patrick M. Colley,Nadeem A. Akbar,Elizabeth A. Borowiec
出处
期刊:American Journal of Rhinology & Allergy [SAGE Publishing]
卷期号:: 19458924261498481-19458924261498481
标识
DOI:10.1177/19458924261498481
摘要

Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who fail medical management are often offered endoscopic sinus surgery (ESS). Dupilumab is also used to treat patients with inadequately controlled CRSwNP. Objective This retrospective cohort study uses a national registry to examine the patterns in healthcare utilization in patients with CRSwNP. Methods A review of the AAO-HNSF Reg-ent SM data registry of CRSwNP patients who underwent ESS or received dupilumab from 2019 to 2025 was performed. The primary outcome of oral antibiotic and corticosteroid free-probability was summarized by Kaplan-Meier estimates and compared between dupilumab treatment and surgery by piecewise Cox proportional hazards model with follow-up time split at 6 months while adjusting for age, sex, ethnicity, race, history of asthma, and allergic rhinitis. Secondary outcomes include polyp recurrence/persistence and repeat imaging. Results 12,944 patients were included. Kaplan-Meier analysis demonstrated the hazard ratio changing over time indicating lower relative hazard of post-intervention antibiotics/corticosteroid use early on among patients who were treated with dupilumab, but the relative hazard of the group increased over time. Antibiotic/corticosteroid use was lower among dupilumab treated patients compared to ESS patients (HR = 0.873; aHR = 0.740; p < 0.0001) in the first 6 months, but they demonstrated higher antibiotic/corticosteroid use thereafter (HR = 1.60, aHR = 1.279; p < 0.0012). There was an increased risk of nasal polyp recurrence/persistence in the dupilumab group during both time periods (aHR = 1.189 & 2.040 before and after 6 months, p < 0.0005 & 0.0001). During the first 6 months, the hazard of repeat imaging was higher among dupilumab patients compared to ESS patients (aHR = 2.098; p < 0.0001). After 6 months, the hazard among dupilumab patients was lower than the ESS patients (aHR = 0.409, p < 0.0001). Conclusion CRSwNP patients treated with dupilumab and ESS demonstrated variable healthcare utilization over time, highlighting the importance of patient selection and shared decision making when considering initiation of dupilumab therapy for CRSwNP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
辛勤尔珍完成签到,获得积分10
8秒前
鲜艳的念寒完成签到,获得积分10
12秒前
小二郎的应助被科研通管家采纳,获得10
21秒前
风吹麦浪的应助被科研通管家采纳,获得20
21秒前
菌菌的应助被科研通管家采纳,获得10
21秒前
45秒前
celinewu完成签到,获得积分10
53秒前
事件的视界完成签到,获得积分10
57秒前
面面面面包完成签到,获得积分10
1分钟前
迷人不可完成签到,获得积分10
1分钟前
空2完成签到 ,获得积分0
1分钟前
爱听歌未来完成签到,获得积分10
1分钟前
1分钟前
曾经凌萱发布了新的文献求助10
1分钟前
1分钟前
www发布了新的文献求助10
1分钟前
1分钟前
小蘑菇的应助被曾经凌萱采纳,获得10
1分钟前
1分钟前
炙热的香菱完成签到,获得积分10
1分钟前
忧虑的怀曼完成签到,获得积分10
1分钟前
复杂曼荷完成签到,获得积分10
1分钟前
1分钟前
小熊的桃子完成签到,获得积分10
1分钟前
科研通AI6.3的应助被www采纳,获得10
1分钟前
molihuakai的应助被面面面面包采纳,获得10
1分钟前
1分钟前
yeke完成签到,获得积分10
2分钟前
随机数学完成签到,获得积分10
2分钟前
2分钟前
完美世界的应助被科研通管家采纳,获得30
2分钟前
Maestro_S的应助被科研通管家采纳,获得10
2分钟前
bkagyin的应助被科研通管家采纳,获得10
2分钟前
菌菌的应助被科研通管家采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
李嘉图发布了新的文献求助30
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179850
求助须知:如何正确求助?哪些是违规求助? 9570035
关于积分的说明 21808147
捐赠科研通 7775536
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557278
邀请新用户注册赠送积分活动 2478844